Arecor and CPI Partner to Enhance Biologics' Compatibility with Containers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Arecor and CPI Partner to Enhance Biologics' Compatibility with Containers


Arecor and the Center for Process Innovation (CPI) Biologics are working on a project to enhance the compatibility of biologics with their containers, and thereby, improve the stability and shelf-life of these medicines throughout transportation and storage. 

The components of vials and syringe can adversely affect the stability of some biologics, causing degradation and making them unsuitable for administration. The collaboration between Arecor and CPI Biologics seeks to address this issue by determining the actual causative components and understanding the degradation mechanisms. The goal is to develop an efficient screening system that can detect compatibility issues during the development of novel biologics. The tool kit will enable the determination of formulation and container selection strategies that will counteract these effects and ensure the stability of biologics in both standard and state-of-the-art delivery devices.

The project starts with a proof-of-concept phase over a six-month period, and if successful, it could potentially transition into a development phase to establish standardized procedures and tools for the biopharmaceutical industry.

This is the first industry partnership that CPI Biologics has undertaken in association with its £38m National Biologics Manufacturing Center (NBMC) and will be performed at CPI’s Wilton laboratories and clean rooms in advance of the opening of the NBMC in 2015.

Source: Arecor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here